At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MYNZ Mainz Biomed B.V.
Post-Mkt 12-26 18:09:22 EST
1.27
+0.10
+8.55%
盘后1.26
-0.01-0.79%
18:06 EST
High1.35Low1.17Vol337.40K
Open1.18D1 Closing1.17Amplitude15.79%
Mkt Cap10.90MTradable Cap10.34MTotal Shares8.58M
T/O422.99KT/O Rate4.15%Tradable Shares8.14M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test
Reuters  ·  12-02
Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test
Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America
Reuters  ·  11-18
Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America
Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA
Reuters  ·  11-12
Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA
Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting
Reuters  ·  11-10
Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting
Mainz Biomed NV to Attend Maxim Growth Summit in New York City
Reuters  ·  10-15
Mainz Biomed NV to Attend Maxim Growth Summit in New York City
Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study
Reuters  ·  10-08
Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study
Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement
Reuters  ·  10-04
Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement
Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting
Reuters  ·  09-30
Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting
Mainz Biomed Reports Financial Results for First Half of 2025
TIPRANKS  ·  09-27
Mainz Biomed Reports Financial Results for First Half of 2025
Mainz Biomed announces commercial launch of ColoAlert in Switzerland
TIPRANKS  ·  09-23
Mainz Biomed announces commercial launch of ColoAlert in Switzerland
Mainz Biomed NV Announces Launch of ColoAlert® in Switzerland and Advances in eAArly DETECT 2 Study
Reuters  ·  09-23
Mainz Biomed NV Announces Launch of ColoAlert® in Switzerland and Advances in eAArly DETECT 2 Study
Mainz Biomed NV expected to post a loss of $2.80 a share - Earnings Preview
Reuters  ·  09-05
Mainz Biomed NV expected to post a loss of $2.80 a share - Earnings Preview
Mainz Biomed Announces Regulatory Approval of ColoAlert for Distribution in the United Kingdom
Reuters  ·  09-02
Mainz Biomed Announces Regulatory Approval of ColoAlert for Distribution in the United Kingdom
Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland
Reuters  ·  08-13
Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit
MT Newswires Live  ·  08-04
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit
Mainz Biomed NV Announces $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Reuters  ·  08-04
Mainz Biomed NV Announces $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed NV Files For Offering 1.5 Million Ordinary Units - SEC Filing
Reuters  ·  07-31
Mainz Biomed NV Files For Offering 1.5 Million Ordinary Units - SEC Filing
Mainz Biomed NV and CARE Partner to Enhance Colorectal Cancer Screening for German Health Insurers
Reuters  ·  07-23
Mainz Biomed NV and CARE Partner to Enhance Colorectal Cancer Screening for German Health Insurers
Mainz Biomed NV Secures Government Funding for Innovative Pancreatic Cancer Screening Project from Rheinland-Pfalz Development Bank
Reuters  ·  07-15
Mainz Biomed NV Secures Government Funding for Innovative Pancreatic Cancer Screening Project from Rheinland-Pfalz Development Bank
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
GlobeNewswire  ·  07-15
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Introduction

Company Name.
Mainz Biomed B.V.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Issue price:
--